Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

Sana Biotechnology, a US-based stem cell medicines developer exploiting Harvard University research, has filed for a $150m initial public offering on the Nasdaq Global Select Market.
The company had confidentially filed in November 2020 and is yet to set any pricing terms. Morgan Stanley, Goldman Sachs, JP Morgan and BofA Securities have been hired as joint bookrunnning managers.
Founded in 2018, Sana Biotechnology is working on hypoimmune stem cells that are able to hide from the patient’s…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in